Cellectis ADR(CLLS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.65 | Insider Own | 3.93% | Shs Outstand | 100.7M | Perf Week | 10.2% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | 17.01% | Insider Trans | - | Shs Float | 69.5M | Perf Month | -22.86% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.18 | Inst Own | 13.18% | Short Float | 0.46% | Perf Quarter | -60.73% |
| Income | -0.07B | P/S | 1.38 | EPS this Y | -19.9% | Inst Trans | 0.26% | Short Ratio | 3.06 | Perf Half Y | -72.66% |
| Sales | 0.06B | P/B | 2.65 | EPS next 5Y | -26.03% | ROA | -21.03% | Short Interest | 0.32M | Perf YTD | -77.69% |
| Book/sh | 0.41 | P/C | 0.47 | EPS past 3/5Y | 33.81% 18.84% | ROE | -94.56% | 52W High | -80.18% ($5.45) | Perf Year | -68.97% |
| Cash/sh | 2.31 | P/FCF | - | Sales past 3/5Y | 56.25% -0.34% | ROIC | -49.84% | 52W Low | 22.62% ($0.88) | Perf 3Y | 6.38% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -13.99% | Gross Margin | 66.25% | Volatility(W/M) | 9.76% 8.56% | Perf 5Y | -89.96% |
| Dividend TTM | - | EV/Sales | 0.28 | Sales Y/Y TTM | -0.11% | Oper. Margin | -116.1% | ATR (14) | 0.12 | Perf 10Y | -93.98% |
| Dividend Ex-Date | - | Quick Ratio | 1.37 | EPS Q/Q | 9.72% | Profit Margin | -115.79% | RSI (14) | 37.82 | Recom | 2.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.37 | Sales Q/Q | -69.19% | SMA20 | -4.3% ($1.13) | Beta | 3.16 | Target Price | $5 |
| Payout | - | Debt/Eq | 2.54 | Earnings | 2026/8/6 | SMA50 | -42.82% ($1.89) | Rel Volume | 0.12 | Prev Close | $1.17 |
| Employees | 229 | LT Debt/Eq | 2.19 | EPS/Sales Surpr. | 16.35% -37.52% | SMA200 | -64.81% ($3.07) | Avg Volume(3M) | 0.10M | Price | $1.08 |
| IPO | 2015/3/25 | Option/Short | Yes/Yes | Trades | 145 | Volume | 12,217 | Change | -7.69% |
🧬 Cellectis is a clinical-stage biotech company developing off-the-shelf CAR-T cell and gene therapies based on its proprietary gene-editing technology (TALEN). Headquartered in France and listed in the U.S. through an ADR, the company is focused on an allogeneic CAR-T immuno-oncology pipeline targeting hematologic cancers.
Over the past 1 year, on the lower side
80% below its 1-year high.
Traded less than usual. That is 12% of its average volume.
CLLS has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -19.9% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $138. Peers typically go for $1,010.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -90.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 13.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IBB iShares Biotechnology ETF <0.01% It ranks #378 of 595 in the industry
Based on market cap of $78M.
FAQ
What kind of company is CLLS?
CLLS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CLLS?
The market cap of CLLS is approximately $78M, ranking 4,610 within its sector.
What is the 52-week high and low for CLLS?
CLLS has recorded a 52-week high of $5.45 and a low of $0.88.
